re-rating overdue, page-4

Agreed Shoonchin.

In my research I've never come across another biotech with the near-medium-long term potential as Allied and since I found it I've constantly urged, and no doubt been irritating in my continual insistence, that my stock market friends read and evaluate Allied's publicly released material.

Over the next 5 years, Cardiocel has every chance of capturing significant market share in multiple markets each worth 100's of millions of $. Over the next 5-10 years there is a chance that Allied will be receiving royalties from their DNA vaccine program although these are still in their very early stages and are not guaranteed to succeed.

For anyone reading this yet to do so, spend a couple of hours reading over Allied's last 2 years of announcements. Fascinating, captivating stuff, and we are seemingly on the cusp of broad regulatory approval for world wide sales. When/if this eventuates then the real fun will begin.